In addition, the IL‐17A expression levels were markedly increased in WHO Grade III and Grade IV compared with that in WHO Grade I‐II (P = 0.011) (Table 2), indicating that IL‐17A might be a prognostic marker for GBM. This evidence concerns the gene IL17A and glioblastoma.